References
- Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653–665. doi:https://doi.org/10.1007/s00424-003-1168-y.
- Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705. doi:https://doi.org/10.1111/j.1476-5381.2009.00430.x.
- Keogh JP. Membrane transporters in drug development. Adv Pharmacol. 2012;63:1–42.
- Zamek-Gliszczynski MJ, Taub ME, Chothe PP, et al. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin Pharmacol Ther. 2018;104(5):890–899. doi:https://doi.org/10.1002/cpt.1112.
- Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008;38(7–8):778–801. doi:https://doi.org/10.1080/00498250801986951.
- Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, et al. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Adv Drug Deliv Rev. 2011;63(1–2):110–118. doi:https://doi.org/10.1016/j.addr.2010.09.008.
- Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol. 2012;52:135–151. doi:https://doi.org/10.1146/annurev-pharmtox-010510-100556.
- Schulte RR, Ho RH. Organic anion transporting polypeptides: emerging roles in cancer pharmacology. Mol Pharmacol. 2019;95(5):490–506. doi:https://doi.org/10.1124/mol.118.114314.
- Erdmann P, Bruckmueller H, Martin P, et al. Dysregulation of mucosal membrane transporters and drug-metabolizing enzymes in ulcerative colitis. J Pharm Sci. 2019;108(2):1035–1046. doi:https://doi.org/10.1016/j.xphs.2018.09.024.
- Ohkura N, Shigetani Y, Yoshiba N, Yoshiba K, Okiji T. Gene expression analysis of membrane transport proteins in normal and lipopolysaccharide-inflamed rat dental pulp. J Endod. 2012;38(5):648–652. doi:https://doi.org/10.1016/j.joen.2012.02.012.
- Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim Biophys Acta. 2009;1788(5):911–917. doi:https://doi.org/10.1016/j.bbamem.2009.03.003.
- Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648. doi:https://doi.org/10.1136/bmj.1.6077.1645.
- Sadarani BN, Majumdar AS. Resveratrol potentiates the effect of dexamethasone in rat model of acute lung inflammation. Int Immunopharmacol. 2015;28(1):773–779. doi:https://doi.org/10.1016/j.intimp.2015.07.038.
- Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica. 2006;36(10–11):963–988. doi:https://doi.org/10.1080/00498250600861751.
- Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251–260. doi:https://doi.org/10.1006/bbrc.2000.2922.
- Sakamoto A, Matsumaru T, Yamamura N, et al. Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J Pharm Sci. 2013;102(9):3395–3406. doi:https://doi.org/10.1002/jps.23606.
- Schuster VL. Prostaglandin transport. Prostaglandins Other Lipid Mediat. 2002;68-69:633–647. doi:https://doi.org/10.1016/S0090-6980(02)00061-8.
- Sayyed K, Vee ML, Abdel-Razzak Z, et al. Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016;363–364:58–71. doi:https://doi.org/10.1016/j.tox.2016.07.011.
- Wang XL, Li T, Li JH, Miao SY, Xiao XZ. The effects of resveratrol on inflammation and oxidative stress in a rat model of chronic obstructive pulmonary disease. Molecules. 2017;22(9):1529. doi:https://doi.org/10.3390/molecules22091529.
- Peng Z, Zhang W, Qiao J, He B. Melatonin attenuates airway inflammation via SIRT1 dependent inhibition of NLRP3 inflammasome and IL-1β in rats with COPD. Int Immunopharmacol. 2018;62:23–28. doi:https://doi.org/10.1016/j.intimp.2018.06.033.
- Chen B, You WJ, Xue S, et al. Overexpression of farnesoid X receptor in small airways contributes to epithelial to mesenchymal transition and COX-2 expression in chronic obstructive pulmonary disease. J Thorac Dis. 2016;8(11):3063–3074. doi:https://doi.org/10.21037/jtd.2016.11.08.
- Qi C, Zhou J, Wang Z, et al. Cigarette smoke extract combined with lipopolysaccharide reduces OCTN1/2 expression in human alveolar epithelial cells in vitro and rat lung in vivo under inflammatory conditions. Int Immunopharmacol. 2020;87:106812. doi:https://doi.org/10.1016/j.intimp.2020.106812.
- Fang X, Wang Z, Qi C, Zhou J, Zhang S, Song J. The changes of MRP2 expression in three kinds of pulmonary inflammation models: the downregulation occurred in cigarette smoke extract (CSE) stimulation group and CSE plus LPS stimulation group, unchanged in LPS stimulation group. Toxicol Mech Method. 2021;31(6):413–424.
- Cui W, Zhang Z, Zhang P, et al. Nrf2 attenuates inflammatory response in COPD/emphysema: crosstalk with Wnt3a/β-catenin and AMPK pathways. J Cell Mol Med. 2018;22(7):3514–3525. doi:https://doi.org/10.1111/jcmm.13628.
- Guan S, Yu P, Cao J, et al. Ginsenoside Rg1 protects against cigarette smoke-induced airway remodeling by suppressing the TGF-β1/Smad3 signaling pathway. Am J Transl Res. 2020;12(2):493–506.
- Li C, Yan Y, Shi Q, et al. Recuperating lung decoction attenuates inflammation and oxidation in cigarette smoke-induced COPD in rats via activation of ERK and Nrf2 pathways. Cell Biochem Funct. 2017;35(5):278–286. doi:https://doi.org/10.1002/cbf.3273.
- de Waart DR, Paulusma CC, Kunne C, Oude Elferink RP. Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006;26(3):362–368. doi:https://doi.org/10.1111/j.1478-3231.2005.01234.x.
- Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008;180(2):1169–1178. doi:https://doi.org/10.4049/jimmunol.180.2.1169.
- Wang L, Xu Z, Chen B, et al. The role of vascular endothelial growth factor in small-airway remodelling in a rat model of chronic obstructive pulmonary disease. Sci Rep. 2017;7:41202. [28117425]
- Possebon L, de Souza Lima Lebron I, Furlan da Silva L, et al. Anti-inflammatory actions of herbal medicines in a model of chronic obstructive pulmonary disease induced by cigarette smoke. Biomed Pharmacother. 2018;99:591–597. doi:https://doi.org/10.1016/j.biopha.2018.01.106.
- Liang S, Meng X, Wang Z, Liu J, Kuang H, Wang Q. Polysaccharide from Ephedra sinica Stapf inhibits inflammation expression by regulating Factor-β1/Smad2 signaling. Int J Biol Macromol. 2018;106:947–954. doi:https://doi.org/10.1016/j.ijbiomac.2017.08.096.
- Haghi M, Ong HX, Traini D, Young P. Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. Pharmacol Ther. 2014;144(3):235–252. doi:https://doi.org/10.1016/j.pharmthera.2014.05.003.
- Zhou J, Qi C, Fang X, et al. DJ-1 modulates Nrf2-mediated MRP1 expression by activating Wnt3a/β-catenin signalling in A549 cells exposed to cigarette smoke extract and LPS. Life Sci. 2021;276:119089. doi:https://doi.org/10.1016/j.lfs.2021.119089.
- Endter S, Francombe D, Ehrhardt C, Gumbleton M. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol. 2009;61(5):583–591. doi:https://doi.org/10.1211/jpp/61.05.0006.
- Kovacsics D, Patik I, Özvegy-Laczka C. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2017;13(4):409–424. doi:https://doi.org/10.1080/17425255.2017.1253679.
- Wen F, Shi M, Bian J, Zhang H, Gui C. Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake. Pharm Biol. 2016;54(2):293–302. doi:https://doi.org/10.3109/13880209.2015.1034326.
- Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharm Genom. 2009;19(2):129–138.
- Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol. 2005;45:689–723. doi:https://doi.org/10.1146/annurev.pharmtox.44.101802.121444.
- Poirier A, Funk C, Lavé T, Noé J. New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Devel. 2007;10(1):74–83.